CR20150576A - Variantes de pertuzumab y su evaluación - Google Patents

Variantes de pertuzumab y su evaluación

Info

Publication number
CR20150576A
CR20150576A CR20150576A CR20150576A CR20150576A CR 20150576 A CR20150576 A CR 20150576A CR 20150576 A CR20150576 A CR 20150576A CR 20150576 A CR20150576 A CR 20150576A CR 20150576 A CR20150576 A CR 20150576A
Authority
CR
Costa Rica
Prior art keywords
pertuzumab
evaluation
variations
molecular weight
weight species
Prior art date
Application number
CR20150576A
Other languages
English (en)
Inventor
Lynn A Gennaro
Yung-Hsiang Kao
Yonghua Zhang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50694078&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20150576(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CR20150576A publication Critical patent/CR20150576A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/416—Systems
    • G01N27/447—Systems using electrophoresis
    • G01N27/44704—Details; Accessories
    • G01N27/44747—Composition of gel or of carrier mixture
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Electrochemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente solicitud describe variantes de pertuzumab. En particular, se revela: una variante de cisteína no apareada que comprende cisteínas Cys23/Cys88 no apareadas en uno o ambos dominios variables livianas de pertuzumab, una variante afucosilada de pertuzumab, una especie de bajo peso molecular (LMWS) de pertuzumab, y una especie de elevado peso molecular (HMWS) de pertuzumab.
CR20150576A 2013-04-16 2015-10-15 Variantes de pertuzumab y su evaluación CR20150576A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361812603P 2013-04-16 2013-04-16
PCT/US2014/034200 WO2014172371A2 (en) 2013-04-16 2014-04-15 Pertuzumab variants and evaluation thereof

Publications (1)

Publication Number Publication Date
CR20150576A true CR20150576A (es) 2015-11-20

Family

ID=50694078

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150576A CR20150576A (es) 2013-04-16 2015-10-15 Variantes de pertuzumab y su evaluación

Country Status (25)

Country Link
US (7) US9815904B2 (es)
EP (2) EP2986643A2 (es)
JP (2) JP2016522176A (es)
KR (2) KR20200085942A (es)
CN (1) CN105121471A (es)
AR (1) AR095863A1 (es)
AU (3) AU2014254086B2 (es)
BR (1) BR112015024926A2 (es)
CA (2) CA2907776C (es)
CL (3) CL2015003049A1 (es)
CR (1) CR20150576A (es)
EA (1) EA201591643A1 (es)
HK (1) HK1211948A1 (es)
IL (2) IL241103B (es)
MA (1) MA38567A1 (es)
MX (2) MX368259B (es)
MY (1) MY173295A (es)
NZ (2) NZ751877A (es)
PE (2) PE20211214A1 (es)
PH (1) PH12015502382A1 (es)
RU (2) RU2019115089A (es)
SG (3) SG10201706045RA (es)
TW (1) TWI554284B (es)
WO (1) WO2014172371A2 (es)
ZA (1) ZA201506594B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
JP5711751B2 (ja) 2009-10-26 2015-05-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ グリコシル化された免疫グロブリンの調製方法
KR20200085942A (ko) 2013-04-16 2020-07-15 제넨테크, 인크. 페르투주맙 변이체 및 그의 평가
JP6914336B2 (ja) * 2016-12-28 2021-08-04 ジェネンテック， インコーポレイテッド 進行したｈｅｒ２発現がんの治療
CR20190376A (es) 2017-01-17 2019-11-20 Genentech Inc Formulaciones de anticuerpos de her2 subcutáneas
HRP20240069T1 (hr) 2017-03-02 2024-03-29 Genentech, Inc. Adjuvantno liječenje her2-pozitivnog raka dojke
AU2018258263A1 (en) * 2017-04-24 2019-10-24 Genentech, Inc. ErbB2/Her2 mutations in the transmembrane or juxtamembrane domain
US20200271663A1 (en) * 2017-09-13 2020-08-27 Mayo Foundation For Medical Education And Research Identification and monitoring of acid hydrolysis products of immunoglobulin heavy chains
JP7259778B2 (ja) 2020-01-31 2023-04-18 トヨタ自動車株式会社 車両、及び自動運転システム
CN113189184B (zh) * 2021-04-28 2022-09-09 浙江大学 含有半胱氨酸的毛细管凝胶电泳样品缓冲液
TW202308701A (zh) 2021-04-29 2023-03-01 大陸商上海匯連生物醫藥有限公司 抗體偶聯藥物的製備方法及應用
KR102511384B1 (ko) 2022-04-14 2023-03-16 지용환 곡물의 손상을 줄일 수 있는 도정기

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3934085A (en) 1984-01-30 1985-08-09 Icrf Patents Ltd. Improvements relating to growth factors
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
ATE155813T1 (de) 1989-05-19 1997-08-15 Genentech Inc Her2 extrazellulare domäne
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
ES2335365T3 (es) 1996-11-27 2010-03-25 Genentech, Inc. Purificacion por afinidad de polipeptido en una matriz de proteina a.
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
IL138034A0 (en) 1998-03-27 2001-10-31 Genentech Inc Apo-2 ligand-anti-her-2 antibody synergism
CN103641885A (zh) 1998-05-06 2014-03-19 基因技术股份有限公司 用离子交换层析纯化蛋白质
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
AU782325B2 (en) 1999-05-14 2005-07-21 Genentech Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP4579471B2 (ja) 1999-06-25 2010-11-10 ジェネンテック， インコーポレイテッド 抗ＥｒｂＢ２抗体を用いる前立腺癌の処置
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
KR20090024308A (ko) 1999-08-27 2009-03-06 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
JP2003534292A (ja) 2000-05-19 2003-11-18 ジェネンテック・インコーポレーテッド Ｅｒｂｂアンタゴニスト癌治療に対する有効な応答の可能性を向上させるための遺伝子検出アッセイ
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
IL156618A0 (en) 2000-12-28 2004-01-04 Altus Biologics Inc Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same
US7435797B2 (en) 2002-04-10 2008-10-14 Genentech, Inc. Anti-HER2 antibody variants
ES2376165T3 (es) * 2002-07-15 2012-03-09 F. Hoffmann-La Roche Ag Tratamiento del c�?ncer con el anticuerpo dirigido contra erbb2 rhumab 2c4.
DK2332996T3 (en) 2002-09-11 2014-12-15 Genentech Inc Purification of anti-Her2 antibodies
JP2006516117A (ja) 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療
WO2005000898A2 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
EP3095793B1 (en) 2003-07-28 2020-03-25 Genentech, Inc. Reducing protein a leaching during protein a affinity chromatography
JP4969440B2 (ja) 2004-04-08 2012-07-04 デビッド， ビー． エイガス， 疼痛治療のためのＥｒｂＢアンタゴニスト
BRPI0510883B8 (pt) 2004-06-01 2021-05-25 Genentech Inc composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
GT200500155A (es) 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
MX2007000723A (es) 2004-07-22 2007-03-12 Genentch Inc Composicion de anticuerpos her2.
CN101052654A (zh) 2004-08-19 2007-10-10 健泰科生物技术公司 具有改变的效应子功能的多肽变体
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005314127A1 (en) 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a HER inhibitor
AU2005315912A1 (en) 2004-12-13 2006-06-22 F. Hoffmann-La Roche Ag Novel pharmaceutical composition containing at least one Dolastatin 10 derivative
KR20130089280A (ko) 2005-01-21 2013-08-09 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
MY152164A (en) 2005-02-23 2014-08-15 Genentech Inc Extending time to disease progression or survival in cancer patients
WO2006096861A2 (en) 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US20070009976A1 (en) 2005-07-06 2007-01-11 Helmut Lenz Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
JP2009539836A (ja) 2006-06-05 2009-11-19 ジェネンテック・インコーポレーテッド ＥＧＦまたはＴＧＦ−αのレベルの上昇が生じている癌患者の生存の延長
US8015939B2 (en) 2006-06-30 2011-09-13 Asml Netherlands B.V. Imprintable medium dispenser
NZ574580A (en) 2006-08-21 2011-12-22 Hoffmann La Roche Her2 tumor therapy with an anti-vegf antibody
WO2008031531A1 (en) 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
BRPI0808418A2 (pt) 2007-03-02 2014-07-22 Genentech Inc Predição de resposta a um inibidor de her
CA2681341A1 (en) * 2007-03-22 2008-09-25 Genentech, Inc. Apoptotic anti-ige antibodies
EP1997534A1 (en) 2007-05-31 2008-12-03 Pierre Fabre Medicament Cancer treatment combination therapy comprising vinflunine and trastuzumab
JP5373776B2 (ja) 2007-06-06 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー 腫瘍抗原に結合する無標識一次モノクローナル抗体と、ｎｉｒフルオレセイン標識で標識された非交差反応性二次モノクローナル抗体から成る組成物
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
DK2171090T3 (da) 2007-06-08 2013-06-10 Genentech Inc Genekspressionsmarkører for tumorresistens over for HER2-inhibitorbehandling
LT3597659T (lt) 2007-07-09 2023-05-10 Genentech, Inc. Disulfidinės jungties redukcijos prevencijos būdas gaminant polipeptidą rekombinantiniu būdu
ES2537352T3 (es) 2007-09-12 2015-06-05 Genentech, Inc. Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapéuticos, y metodos para su uso
NZ584514A (en) * 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
SI2215117T2 (en) 2007-10-30 2018-04-30 Genentech, Inc. Purification of the antibody by cation exchange chromatography
CA2713342A1 (en) * 2008-01-30 2009-08-13 Abbott Laboratories Compositions and methods for crystallizing antibody fragments
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
JP2011513432A (ja) 2008-03-06 2011-04-28 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ及びＨＥＲアンタゴニストの併用療法
TWI527593B (zh) 2008-03-18 2016-04-01 建南德克公司 抗ｈｅｒ２抗體-藥物結合物及化療劑之組合及使用方法
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
FR2942799B1 (fr) * 2009-03-06 2011-02-25 Lfb Biotechnologies Anticorps monoclonal anti-rhesus d
EP2435071A1 (en) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AU2010335282B2 (en) * 2009-12-22 2015-05-21 Roche Glycart Ag Anti-HER3 antibodies and uses thereof
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
MX2013006392A (es) 2010-12-09 2013-12-06 Genentech Inc Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
SG194472A1 (en) * 2011-01-28 2013-12-30 Ca Nat Research Council Engineering of immunoglobulin domains
WO2012120004A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
KR102679155B1 (ko) 2011-10-14 2024-06-28 제넨테크, 인크. Her2 이량체화 억제제인 페르투주맙의 용도 및 이를 포함하는 제조품
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
EP2793941A1 (en) 2011-12-23 2014-10-29 F.Hoffmann-La Roche Ag Articles of manufacture and methods for co-administration of antibodies
AU2013273489B9 (en) 2012-06-08 2018-08-23 F. Hoffmann-La Roche Ag Mutant selectivity and combinations of a phosphoinositide 3 Kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
JP6998646B2 (ja) 2012-11-30 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
KR20200085942A (ko) 2013-04-16 2020-07-15 제넨테크, 인크. 페르투주맙 변이체 및 그의 평가
MX2016007887A (es) 2013-12-17 2016-10-28 Genentech Inc Metodos de tratamiento de canceres positivos a her2 usando antagonistas de union del eje de pd-1 y anticuerpos anti-her2.

Also Published As

Publication number Publication date
KR20150143649A (ko) 2015-12-23
CL2015003049A1 (es) 2016-06-10
US20200157238A1 (en) 2020-05-21
MX368259B (es) 2019-09-25
EP3800204A1 (en) 2021-04-07
WO2014172371A3 (en) 2015-01-08
US9969811B2 (en) 2018-05-15
US20140308277A1 (en) 2014-10-16
SG11201508536PA (en) 2015-11-27
JP2020015719A (ja) 2020-01-30
RU2737727C2 (ru) 2020-12-02
CN105121471A (zh) 2015-12-02
EP2986643A2 (en) 2016-02-24
MY173295A (en) 2020-01-14
CL2017002445A1 (es) 2018-03-16
WO2014172371A2 (en) 2014-10-23
US20180037661A1 (en) 2018-02-08
KR20200085942A (ko) 2020-07-15
US20230047103A1 (en) 2023-02-16
AU2018241141A1 (en) 2018-10-25
MX2015013898A (es) 2016-07-08
RU2015141520A (ru) 2017-05-22
US20180037662A1 (en) 2018-02-08
MA38567A1 (fr) 2017-09-29
AU2014254086B2 (en) 2018-07-05
BR112015024926A2 (pt) 2017-10-10
AU2014254086A1 (en) 2015-10-08
CA2907776C (en) 2020-04-14
JP2016522176A (ja) 2016-07-28
AR095863A1 (es) 2015-11-18
AU2018241141B2 (en) 2019-11-07
US20180037660A1 (en) 2018-02-08
EA201591643A1 (ru) 2016-02-29
IL241103A0 (en) 2015-11-30
ZA201506594B (en) 2018-11-28
CA2907776A1 (en) 2014-10-23
NZ712012A (en) 2020-04-24
MX2019005151A (es) 2022-06-27
US9815904B2 (en) 2017-11-14
PE20211214A1 (es) 2021-07-05
IL275398A (en) 2020-07-30
HK1211948A1 (en) 2016-06-03
AU2019253804A1 (en) 2019-11-14
SG10201911353WA (en) 2020-02-27
CA3071678A1 (en) 2014-10-23
CL2019002244A1 (es) 2019-11-29
PH12015502382A1 (en) 2016-02-22
NZ751877A (en) 2020-04-24
TW201442725A (zh) 2014-11-16
IL241103B (en) 2020-07-30
PE20151769A1 (es) 2015-12-11
US20190345258A1 (en) 2019-11-14
RU2019115089A (ru) 2019-06-11
SG10201706045RA (en) 2017-08-30
TWI554284B (zh) 2016-10-21

Similar Documents

Publication Publication Date Title
CR20150576A (es) Variantes de pertuzumab y su evaluación
WO2014124285A3 (en) Illumination device providing direct and indirect illumination
SG11201709751SA (en) Pyrromethene-boron complex, color-changing composition, color-changing film, light source unit including same, display, and lighting
BR112015022763A2 (pt) sensores de oxigênio
ES1107816Y (es) Dispositivo de excitación de lámparas led.
BR112016002391A2 (pt) composições tópicas e métodos de uso das mesmas
BR112015023030A2 (pt) indicador de esterilização e processo de esterilização
BR112016024494A2 (pt) análogos de peptídeo com sonda(s) de aminoácidos ramificados
CR20150151A (es) Sistema de control de elución de rubidio
BR112016010770A2 (pt) : válvula com indicador de situações positiva e negativa
FI20135876A (fi) Optometrinen instrumentti, jossa on kohdistusvälineet ja menetelmä optometrisen instrumentin kohdistamiseksi
BR112015016330A2 (pt) aparelho de exibição que fornece interação com usuário .
IL238353A0 (en) A device for emitting light with a wide and continuous frequency range and its use
AU352854S (en) LED light
FR3003116B1 (fr) Circuit avec compensation lineaire de gradation de del
CL2015002389A1 (es) Composiciones herbicidas que contienen isoxabena y flufenaceto.
BR112018009479A2 (pt) dispositivo e método antifalsificação
BR112017005532A2 (pt) acionamento por correia com extensão de compressão
FI20155513A (fi) Sovitelma refraktometrin mittaikkunan yhteydessä ja refraktometri
BR112015027123A2 (pt) embarcação com uma cavidade aérea no fundo
BR112016002062A2 (pt) sistema de transmissão que compreende uma polia de direcionamento e uma correia dentada úmida com óleo
AR098670A1 (es) Inhibidor de sglt1
DK3024815T3 (da) Fedtamid baseret på lactam eller aminosyre og anvendelse som organisk geldanner
BR112016012752A2 (pt) variantes de glicoamilase
BR112016023650A2 (pt) dispositivo de iluminação portátil